Drug Profile
Research programme: antibody therapeutics - PharmAbcine
Alternative Names: anti-KDR mAb; DIG KT; PIG KM; PMC 001; PMC 201; PMC-002; SSS-25; TRPH 011; VEGFR-2/TIE-2 - PharmAbcine/Triphase Accelerator CorporationLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator PharmAbcine
- Developer PharmAbcine; Triphase Accelerator Corporation
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors; Proto-oncogene protein c-met inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
- Discontinued Glioblastoma; Inflammation; Pancreatic cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 09 Dec 2021 Preclinical development is ongoing in Canada (Parenteral) (PharmAbcine pipeline, December 2021)
- 09 Dec 2021 Discontinued - Preclinical for Glioblastoma in Canada (Parenteral) (PharmAbcine pipeline, December 2020)